An impressive new study published in Nature is pointing to a new kind of treatment to protect the vulnerable from COVID-19. The research revealed an old drug derived from bear bile and used for liver ...

Ursodeoxycholic acid (UDCA) is the standard first-line therapy for primary biliary cholangitis. In this large retrospective cohort study of primary biliary cholangitis patients, UDCA treatment was ...

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA ...

The approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in management of the condition, substantially reducing the risk of liver ...

As the management landscape of primary biliary cholangitis (PBC) changes, new second-line options offer effective alternatives for patients who respond inadequately to standard first-line treatment ...

Primary biliary cholangitis (PBC) damages small bile ducts, causing bile buildup that can scar the liver. Over time, this can lead to liver failure or bleeding varices. Ursodeoxycholic acid (UDCA) is ...

Salk scientists discover that removing bile acid-creating protein BAAT and adding bile acid UDCA controls tumor growth in mice with liver cancer; UDCA dietary supplements may be quick solution to ...